Viatris Inc.

VTRS Healthcare Drug Manufacturers Specialty & Generic

Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024.

Revenue
−0.28%
EPS
−157.5%
Free cash flow
+38.8%
Total debt
−18.1%

Quarter to September 2026, against a year earlier

19.83 0.86 +4.53%
Market cap
$21.8B
P/E
0.0×
Fwd P/E
82.6×
Dividend yield
2.42%
F-score
4/9
Altman Z
0.61
Beneish M
−3.29
Dividend safety
37/100
Older periods Dec '25 Mar '26 Jun '26 Sep '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
1.02 1.07 1.25 1.38
P/FCF ratio
7.52 9.07 9.77 9.90
P/Operating CF
17.87 40.20 48.38 53.31
P/B ratio
0.99 1.06 1.30 1.43
EV/Sales
1.93 1.93 2.10 2.16
EV/EBITDA
9.01 9.55 11.39 11.74
EV/FCF
14.27 16.35 16.36 15.51
Current Ratio
1.38 1.60 1.58 1.55
Net Debt/EBITDA
22.80 21.03 18.37 0.00
Debt/Equity
0.98 0.98 0.94 0.97
Earnings Yield
(23.81%) (1.95%) (2.27%) (3.01%)
Free Cash Flow Yield
13.30% 11.03% 10.23% 10.10%
Free Cash Flow per Share
0.55 0.23 0.29 0.00
Book value per Share
12.57 12.69 12.26 11.91
Free Cash Flow
640.40 268.00 336.20 896.50
EV/EBIT
0.00 201.94 0.00 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 6 Nov 2026